Yazar: Alp Eren Güngör

2BEHRJJ (200414) -- BEIJING, April 14, 2020 (Xinhua) -- A staff member displays samples of the COVID-19 inactivated vaccine at Sinovac Biotech Ltd., in Beijing, capital of China, March 16, 2020. China has approved two COVID-19 inactivated vaccine candidates for clinical trials, according to the State Council joint prevention and control mechanism against the coronavirus Tuesday. The two vaccine candidates are developed by Wuhan Institute of Biological Products under the China National Pharmaceutical Group (Sinopharm) and Sinovac Research and Development Co., Ltd, a company based in Beijing. Clinical

Hiçbir Şey Bitmedi

Tarih 1 Ocak 2020. Çinin Wuhan kentinde yaşayan bir yaşlı teyze evden çıkıp evin ihtiyaçlarını almaya gitmiştir. Fakat bu teyzemiz bilinmeyen bir bulaşıcı virüse sahiptir. […]

Devamını oku